How have CVM shares performed in 2024?

CEL-SCI's stock was trading at $2.72 at the start of the year. Since then, CVM shares have decreased by 41.9% and is now trading at $1.58. View the best growth stocks for 2024 here .

When is CEL-SCI's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CVM earnings forecast .

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSE:CVM) posted its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.14) earnings per share for the quarter.

When did CEL-SCI's stock split?

CEL-SCI's stock reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of CEL-SCI?

Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:CVM

CEL-SCI (CVM) Stock Price, News & Analysis

→ Nerd Investor Reveals Secret To Make Money With A.I. (From InvestorPlace) (Ad)

Free CVM Stock Alerts

$1.58

-0.05 (-3.07%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.53
▼
$1.68
50-Day Range: $1.58
▼
$3.08
52-Week Range: $1.04
▼
$3.23

Volume: 175,064 shs
Average Volume: 307,620 shs
Market Capitalization: $85.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get CEL-SCI alerts:

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About CEL-SCI Stock (NYSE:CVM)

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

CVM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CVM Stock News Headlines

April 15, 2024 | finance.yahoo.com

CVM: Parallel Engagement on Four Fronts

April 12, 2024 | msn.com

Scientists produce in vitro model of cell differentiation during early facial development

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 10, 2024 | americanbankingnews.com

CEL-SCI (NYSE:CVM) Trading Down 3.9%

April 9, 2024 | msn.com

Researchers discover two vesicle fusion mechanisms while studying vesicle movement in living cells

April 6, 2024 | seekingalpha.com

CVM CEL-SCI Corporation

March 28, 2024 | msn.com

Cross-species insights: Study finds calcium link in plant and animal immunity

March 19, 2024 | stockhouse.com

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 19, 2024 | finance.yahoo.com

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

March 11, 2024 | msn.com

Researchers reveal a new mechanism that regulates intestinal stem cells

March 6, 2024 | businesswire.com

CEL-SCI Corporation Issues Letter to Shareholders

February 23, 2024 | finance.yahoo.com

CVM Apr 2024 4.000 call

February 15, 2024 | finance.yahoo.com

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

February 15, 2024 | businesswire.com

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

February 13, 2024 | finance.yahoo.com

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

February 12, 2024 | seekingalpha.com

Cel-Sci: Fabulous Story Stock Works To Pass Muster With FDA

February 9, 2024 | msn.com

Why CEL-SCI Corporation (CVM) Shares Are Diving

February 9, 2024 | finance.yahoo.com

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

February 6, 2024 | stockhouse.com

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

January 31, 2024 | stockhouse.com

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

January 8, 2024 | finance.yahoo.com

CVM: Fiscal Year 2023 in Review

December 22, 2023 | finance.yahoo.com

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

December 14, 2023 | morningstar.com

CEL-SCI Corp CVM

December 8, 2023 | finance.yahoo.com

CVM: NICE To Have Your Support

December 4, 2023 | barrons.com

UK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard of Care for Head & Neck Cancer

November 20, 2023 | benzinga.com

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock

See More Headlines

Receive CVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSE:CVM
CUSIP: N/A
CIK: 725363
Web: cel-sci.com
Phone: 703-506-9460
Fax: 703-506-9471
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.68)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,190,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -204.28%
Return on Assets: -95.72%

Debt

Debt-to-Equity Ratio: 0.75
Current Ratio: 1.26
Quick Ratio: 0.78

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.28 per share
Price / Book: 5.64

Miscellaneous

Outstanding Shares: 53,980,000
Free Float: 46,390,000
Market Cap: $85.29 million
Optionable: Optionable
Beta: 1.29

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Geert R. Kersten Esq. (Age 65)
Chief Executive & Financial Officer, Treasurer and Director
Comp: $702.79k
Ms. Patricia B. Prichep (Age 73)
Senior VP of Operations & Corporate Secretary
Comp: $295.18k
Dr. Eyal Talor Ph.D. (Age 68)
Chief Scientific Officer
Comp: $351.88k
Dr. Daniel H. Zimmerman Ph.D. (Age 83)
Senior Vice President of Research & Cellular Immunology
Comp: $46.08k
Mr. John Cipriano (Age 82)
Senior Vice President of Regulatory Affairs
Comp: $246.97k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CVM Stock Analysis - Frequently Asked Questions

How have CVM shares performed in 2024?: CEL-SCI's stock was trading at $2.72 at the start of the year. Since then, CVM shares have decreased by 41.9% and is now trading at $1.58.
View the best growth stocks for 2024 here.
When is CEL-SCI's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our CVM earnings forecast.
How were CEL-SCI's earnings last quarter?: CEL-SCI Co. (NYSE:CVM) posted its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.14) earnings per share for the quarter.

When did CEL-SCI's stock split?: CEL-SCI's stock reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
How do I buy shares of CEL-SCI?: Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CVM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial